Generic Name and Formulations:
Clomiphene citrate 50mg; scored tabs.
Various generic manufacturers
Indications for Clomiphene:
Induction of ovulation.
50mg daily for 5 days beginning on the 5th day of menstrual cycle; max 3 courses. If ovulation does not occur after 1st course, increase dose to 100mg daily for 2nd course; max 100mg/day for 5 days. See full labeling.
Primary ovarian failure. Ovarian cysts. Uterine leiomyomas. Abnormal uterine bleeding. Thrombophlebitis. Liver disease. Depression. Uncontrolled thyroid or adrenal dysfunction. Intracranial lesions. Pregnancy (Cat.X).
Perform initial complete pelvic and endocrinologic exam. If ovarian enlargement occurs, hold dose until ovaries return to pretreatment size, and reduce dosage or duration of next course. Polycystic ovary syndrome. Discontinue if visual disorders occur. Metabolism disorders (eg, hypertriglyceridemia). Preexisting or family history of hyperlipidemia: monitor plasma triglycerides periodically. Nursing mothers.
Ovarian enlargement, vasomotor flushes, abdominal/pelvic discomfort/distention/bloating, nausea, vomiting, breast discomfort, visual symptoms (eg, blurred vision, lights, floaters), headache, abnormal uterine bleeding; multiple births, pancreatitis.
Formerly known under the brand name Serophene.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML